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Abstract
In this review, we present an overview of the main aspects related to
the statistical evaluation of medical tests for diagnosis and prognosis.
Measures of diagnostic performance for binary tests, such as sensitivity,
specificity, and predictive values, are introduced, and extensions to the
case of continuous-outcome tests are detailed. Special focus is placed
on the receiver operating characteristic (ROC) curve and its estima-
tion, with the topic of covariate adjustment receiving a great deal of
attention. The extension to the case of time-dependent ROC curves for
evaluating prognostic accuracy is also touched upon. We apply several
of the approaches described to a dataset derived from a study aimed to
evaluate the ability of HOMA-IR (homeostasis model assessment of in-
sulin resistance) levels to identify individuals at high cardio-metabolic
risk and how such discriminatory ability might be influenced by age
and gender. We also outline software available for the implementation
of the methods.
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1. INTRODUCTION
Evaluating and ranking the performance of medical tests for screening and diagnosing dis-
ease greatly contributes to the health promotion of individuals and communities. Through-
out this article we will be using the term ‘diagnostic test’ to broadly include any continuous
classifier, such as, a single biological marker or a univariate composite score obtained from a
combination of biomarkers. The primary goal of a diagnostic test is to distinguish between
individuals with and without a well-defined condition (termed ‘disease’, with ‘nondisease’
used to indicate the absence of the condition). For some diseases, there might exist a gold
standard test that perfectly classifies all individuals as diseased or nondiseased. However,
gold standard tests (e.g., a biopsy) might not only be expensive, but also invasive and
potentially harmful. Economic and/or ethical reasons may thus preclude the routine use
of gold standard tests except when sufficient evidence is present. As a consequence, much
effort has been placed in developing new candidate tests that are less invasive, costly, or
easier to apply than the gold standard counterpart. Nevertheless, new candidate tests are
rarely perfect. Thus, a critical step prior to approving the use of a diagnostic test in clinical
practice is to rigorously vet its ability to distinguish diseased from nondiseased individuals.
Compared to the truth, i.e., to the diagnosis made by the gold standard test, which we
assume to be available, interest lies in quantifying the misclassification errors made by the
test under investigation and in deciding whether yet with such errors, the test may still be
suitable for routine use. It is worth noting that although we focus on medical diagnosis, the
problem of binary classification is such a wide one, finding applications in fields as diverse
as finance (e.g., customer likely to incur in default or not) and cyber security (e.g., email
messages are spam or not), to name only two.
The receiver operating characteristic (ROC) curve (Metz 1978) is the most popular
used tool for evaluating the discriminatory ability of continuous-outcome tests, which are
our focus. ROC curves thus receive a great deal of attention in this article. The ROC curve
was developed during World War II to assess the ability of radar operators to differentiate
signal (e.g., enemy aircraft) from noise (e.g., flock of birds). Its expansion to other fields was
prompt (e.g., psychology) and it was first extensively used in radiology to evaluate medical
imaging devices (Metz 1986). Thanks to advancements in technology, with a vast array
of ways to diagnose disease or to predict its progression available and with new diagnostic
tests or biomarkers continuously being studied, the ROC curve is, nowadays, a key tool in
medicine. ROC curves are also widely used in machine learning to evaluate classification
algorithms. Quoting Gneiting & Vogel (2018, p. 1) there has been an ‘(...) astonishing
rise in the use of ROC curves in the scientific literature. In 2017, nearly 8,000 papers were
published that use ROC curves, up from less than 50 per year through 1990 and less than
1,000 papers annually through 2002.’.
The aim of this article is to present an overview of the main statistical concepts and
methods for evaluating the accuracy of medical tests, with ROC curves naturally receiving
the main emphasis. The reader is referred to the books by Pepe (2003), Krzanowski & Hand
(2009), Zhou et al. (2011), Broemeling (2016) and papers cited in this article for further
coverage of the topic.
The remainder of this article is structured as follows: In Section 2 we describe the
HOMA-IR dataset, which is used as an illustrative example throughout the article. Mea-
sures of diagnostic accuracy, including the ROC curve and some methods for its estimation,
are introduced in Section 3. The topic of covariate-adjustment in ROC curves is reviewed
in Section 4, while in Section 5 time-dependent ROC curves are discussed. In Section 6
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we outline available software in R (R Core Team 2020). Finally, in Section 7, we offer some
conclusions and thoughts on further topics.
2. ILLUSTRATIVE EXAMPLE
Insulin resistance (IR) is a feature of disorders such as type 2 diabetes mellitus and is
implicated in obesity, hypertension, cancer, or autoimmune diseases. Also, IR is associated
with cardiovascular diseases, and some studies have shown that IR may be an important
predictor of cardiovascular disease risk. The HOmeostasis Model Assessment of IR (HOMA-
IR) is widely used in epidemiological studies and in clinical practice to estimate IR and has
proved to be a robust tool for the surrogate assessment of IR. We will exemplify some of
the different measures and methods described in this paper when it comes to studying the
capacity of HOMA-IR levels to detect patients with higher cardio-metabolic risk and to
ascertaining the possible effect of both age and gender on the accuracy of this measure.
The purpose here is merely illustrative, and we refer the interested reader to Gayoso-Diz
et al. (2013), where the objective was originally proposed and studied, for more details and
references.
In particular, as an accurate indicator of the presence of cardio-metabolic risk (i.e.,
presence of ‘disease’), we use a diagnosis of metabolic syndrome as defined by the Interna-
tional Diabetes Federation (International Diabetes Federation 2006) criteria, under which
metabolic syndrome is defined as the presence of central obesity (defined as waist circum-
ference with ethnicity specific values) plus any two of the following four risk factors: (1)
reduced HDL-cholesterol or specific treatment for this lipid abnormality, (2) raised systolic
or diastolic blood pressure or treatment of previously diagnosed hypertension, (3) raised
fasting plasma glucose or previously diagnosed type 2 diabetes, (4) raised triglycerides or
specific treatment for this lipid abnormality.
Regarding the study population, it corresponds to the individuals enrolled in the
EPIRCE study (Estudio Epidemiolo´gico de la Insuficiencia Renal en Espan˜a) (Otero et al.
2005, 2010), which is an observational cross-sectional study that included a randomly se-
lected sample of Spanish individuals aged 20 years and older, stratified by age, gender, and
residence. For the analyses shown here, 2212 individuals out of 2459 were selected (age
range in years 20–92). Subjects with diabetes (247, 10.0% of the total sample) were ex-
cluded. Of the total of 2212 subjects, 41.0% were men (769 nondiseased and 135 diseased)
and 59.0% women (1194 nondiseased and 114 diseased). All participants were Caucasians.
Table 1 presents some summary statistics of the HOMA-IR levels (log-transformed) for men
and women, as well as, for different age strata. In turn, Figure 1 depicts, separately for men
and women, the estimated density functions of the log HOMA-IR levels in the diseased and
nondiseased populations. As can be observed, both in men and women, individuals with
metabolic syndrome tend to have higher HOMA-IR levels and these levels also vary with
age.
3. POPULAR MEASURES OF ACCURACY
3.1. Binary Tests
Although our focus is on tests measured on a continuous scale, we start by defining measures
of classification accuracy for binary tests as they provide the natural starting point for what
comes next. A binary test is a test for which there are only two possible outcomes, usually
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Table 1 Median (interquartile range) of the (log) HOMA-IR levels in diseased and
nondiseased populations, males and females, and for four gender strata based on quar-
tiles.
Diseased Nondiseased
Global sample 0.91 (0.50, 1.25) 0.51 (0.13, 0.85)
Gender
Women 0.89 (0.49, 1.26) 0.51 (0.14, 0.82)
Men 0.92 (0.52, 1.25) 0.50 (0.11, 0.89)
Age
≤ 35 1.06 (0.64, 1.34) 0.53 (0.18, 0.85)
(35, 47] 1.04 (0.69, 1.35) 0.47 (0.09, 0.82)
(47, 60] 0.87 (0.52, 1.19) 0.47 (0.08, 0.81)
> 60 0.82 (0.42, 1.25) 0.60 (0.17, 0.92)
Men Women
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Figure 1
Estimated density functions of log HOMA-IR levels obtained by fitting a Dirichlet process mixture of normals model to
each population and separately for men and women.
denoted as positive or negative for the condition or disease of interest. Let Y be a binary
variable denoting the diagnostic test outcome, with Y = 1 indicating a positive test result for
disease, and Y = 0 indicating a negative test result for disease. Further, let D be the binary
variable that denotes the true disease status, and let D = 1 denote the presence of disease
and D = 0 indicate its absence. The accuracy of a test is defined as its ability to distinguish
between diseased and nondiseased individuals and can be measured by its true positive and
true negative fractions. The true positive fraction of a test, TPF, also known as sensitivity,
is the probability that a diseased individual tests positive, that is, TPF = Pr(Y = 1 |
D = 1). The true negative fraction, TNF, also known as specificity, is the probability that
a nondiseased subject tests negative, i.e., TNF = Pr(Y = 0 | D = 0). The ideal test
would correctly classify all diseased and nondiseased individuals, but the tests routinely
used in practice are relatively inexpensive and classification errors do occur. Specifically,
two types of misclassification are possible: a diseased individual can test negative and a
nondiseased individual can test positive. The magnitude of such misclassification errors is
measured through the false negative fraction (FNF) and the false positive fraction (FPF),
which are defined as, FNF = Pr(Y = 0 | D = 1) and FPF = Pr(Y = 1 | D = 0). Clearly,
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FNF = 1 − TPF and FPF = 1 − TNF. An ideal test is one for which the TPF and TNF
are both equal to one or, equivalently, where the FNF and FPF are both equal to zero.
Obviously, the closer such quantities are to these ideal values, the more the classification
made by the test is to be trusted. Nevertheless, a test can be useful even when these
quantities are smaller than the ideal values. The criterion whereby the validity of a test
is established in practice depends entirely on the context in which it is to be applied. For
example, a false negative outcome can be life-threatening with diseased individuals failing
to receive prompt treatment while, on the other hand, a false positive outcome may result
in the physical, emotional, and financial burdens resulting from further testing or even
unnecessary treatment.
The true positive and negative fractions quantify how well the test performs among
subjects with and without the condition, respectively, which is important for public health
concerns. In the clinical setting, however, interest resides in the opposite question, i.e., how
well the test outcome predicts the true disease status. The question of interest is: Given
that an individual has a positive (negative) test outcome, what is the probability of being
diseased (nondiseased)? This leads to the positive and negative predictive values (PPV and
NPV, respectively)
PPV = Pr(D = 1 | Y = 1) = piTPF
piTPF + (1− pi)FPF , 1.
NPV = Pr(D = 0 | Y = 0) = (1− pi)TNF
(1− pi)TNF + piFNF , 2.
where pi = Pr(D = 1) is the prevalence of the disease in the source population. An ideal
test has PPV and NPV both equal to 1, that is, it predicts disease status perfectly. On the
other hand, for a noninformative test one has that PPV = pi and NPV = 1−pi, i.e., the test
has no information about the true disease status or, in other words, information about the
test outcome is independent of disease status. Since the predictive values depend on the
prevalence of the disease, their interpretation must be cautious. For instance, a low PPV
may be due to a low disease prevalence or to a test that poorly reflects the true disease
status.
It has been suggested (e.g., Pepe 2003, Chapter 2) to use the TPF and FNF for quanti-
fying the inherent accuracy of a test, as these classification probabilities quantify how well
a given test reflects true disease status. Predictive values, in turn, quantify the clinical or
practical value of the test, rather than its accuracy. That is, diagnostic accuracy must refer
to the quality of the information yielded by the test (i.e., its TPF and TNF), something
that has to be distinguished from the usefulness or practical utility of such information
(quantified by the predictive values). It is worth mentioning at this stage that as the TPF
and TNF are independent of disease’s prevalence, they can be estimated from case-control
studies. By opposition, estimation of the predictive values requires that the prevalence is
known or that it can be estimated from the data.
3.2. Continuous Tests
Although some tests are naturally dichotomous, such as commercial home pregnancy tests
or bacterial cultures, many tests are continuous (e.g., HOMA-IR levels for predicting the
presence of cardio-metabolic risk). The question arising is how to classify an individual as
diseased or nondiseased based on his/her test result, which is now measured on a continuous
scale. The simplest classification is based on a cutoff or threshold value, say c, such that a
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test result with Y ≥ c is considered positive for disease and if Y < c the test is considered
negative. Therefore, each threshold value chosen gives rise to a corresponding TPF and
TNF, or equivalently, to a TPF and FPF, that is,
TPF(c) = Pr(Y ≥ c | D = 1) = Pr(YD ≥ c) = 1− FD(c),
FPF(c) = Pr(Y ≥ c | D = 0) = Pr(YD¯ ≥ c) = 1− FD¯(c),
where we use the subscripts D and D¯ to index related quantities to the diseased (D = 1) and
nondiseased (D = 0) populations, and with FD and FD¯ denoting the cumulative distribution
function of test results in the diseased and nondiseased populations, respectively. It is clear
that there will be as many pairs of true and false positive fractions as of threshold values
chosen and comparing all of them would be impractical. This leads us to the popular ROC
curve, which represents nothing more than the plot of the FPF versus the TPF as the
threshold value used for defining a positive test result is varied, that is
{(FPF(c),TPF(c)) : c ∈ R} = {(1− FD¯(c), 1− FD(c)) : c ∈ R}.
The ROC curve thus provides a visual description of the tradeoff between the FPF and
TPF as the threshold c changes. For p = FPF(c) = 1 − FD¯(c), the ROC curve can be
equivalently represented as
{(p,ROC(p)) : p ∈ [0, 1]}, with ROC(p) = 1− FD{F−1D¯ (1− p)}. 3.
Further advantages afforded by the ROC curve as a measure of a test’s accuracy are that:
(a) it is not dependent on disease prevalence, (b) it is independent of the units in which
diagnostic test results are measured, thereby enabling ROC curves of different diagnostic
tests, and thus their diagnostic accuracy, to be compared, and (c) it is invariant to strictly
increasing transformations of the diagnostic test result Y . We shed some light on how
ROC curves should be interpreted. ROC curves measure the amount of separation between
the distribution of test outcomes in the diseased and nondiseased populations (see Figure
2). When the distributions of test results in the two populations completely overlap, then
the ROC curve is the diagonal line of the unit square, with FPF(c) = TPF(c) for all c,
indicating a noninformative test. The more separated the distributions of test outcomes,
the closer the ROC curve is to the point (0, 1) and, consequently, the better the diagnostic
accuracy. A curve that reaches the point (0, 1) has FPF(c) = 0 and TPF(c) = 1 for some
threshold c and, hence, corresponds to a test that perfectly determines the true disease
status. An ROC curve which lies below the diagonal line implies that the test is worse
than useless, but this issue can be easily overcome by reversing the classification rule, i.e.,
to say that an individual is diseased when his/her test outcome is below c and nondiseased
otherwise. Related to the ROC curve is the notion of placement value (Pepe & Cai 2004),
which is simply a standardisation of test outcomes with respect to a reference population.
Let UD = 1 − FD¯(YD) be the placement value of diseased individuals with respect to the
nondiseased population. This variable UD quantifies the degree of separation between the
diseased and nondiseased populations. Specifically, if test outcomes in the two populations
are highly separated, the placement of most diseased individuals is at the upper tail of
the nondiseased distribution and so most of them will have small UD values. In turn,
if the two populations overlap substantially, UD will have a Uniform(0, 1) distribution.
Interestingly, the ROC curve turns out to be the cumulative distribution function of UD,
that is, Pr(UD ≤ p) = ROC(p).
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Figure 2
Hypothetical densities of test outcomes in the diseased (dotted line, orange) and nondiseased (solid line, blue) populations
(top) along with the corresponding ROC curves (bottom).
A standard way to summarise the information provided by the ROC curve is to calculate
the area under the ROC curve (AUC), which is defined as
AUC =
∫ 1
0
ROC(p)dp.
In addition to its geometric definition, the AUC has also a probabilistic interpretation (see,
e.g., Pepe 2003, p. 78)
AUC = Pr (YD ≥ YD¯) , 4.
that is, the AUC is the probability that the test outcome for a randomly chosen diseased
subject exceeds the one exhibited by a randomly selected nondiseased individual. The AUC
is equal to 1 for a perfect test and it is equal to 0.5 for a test with no discriminatory power
(see Figure 2). Another global summary measure of diagnostic accuracy is the Youden
index(YI) (Youden 1950), defined as
YI = max
c
{TPF(c) + TNF(c)− 1}
= max
c
{FD¯(c)− FD(c)} 5.
= max
p
{ROC(p)− p}. 6.
When the distributions of test outcomes completely overlap YI = 0, whereas when they
are completely separated YI = 1. An YI below 0 indicates that the classification rule for
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defining a positive test result must be reversed. It is worth mentioning that the YI is
equivalent to the Kolmogorov–Smirnov measure of distance between the distributions of
test outcomes in the diseased and nondiseased populations. Note that from Equation 6,
the YI can also be interpreted as the maximum vertical distance between the ROC curve
and the chance diagonal. An appealing feature of the YI not present in the AUC is that
it provides a criterion for choosing the threshold value to diagnose subjects in practice.
The criterion is to choose the value c∗ that maximises Equation 5 or c∗ = F−1
D¯
(1 − p∗),
with p∗ being the value that maximises Equation 6. For further measures of diagnostic
accuracy, such as partial areas under the ROC curve, where only a subset of FPFs or TPFs
are considered, we refer the reader to Pepe (2003, Chapter 4).
We finish this section highlighting that the ROC curve, as usually defined, measures
the discriminatory capacity of a test under the particular classification rule that says that
individuals with a test outcome larger than a pre-specified threshold are diseased, while
those with a test outcome lower than the threshold are classified as nondiseased. The
appropriateness of such classification rule relies on the standard assumption that larger
test outcomes are more indicative of disease. However, this is not always the case. For
instance, not only high but also low test results might be associated with disease. An
example is provided in Mart´ınez-Camblor et al. (2017). Therefore, one should be aware
that the classification rule on which the usual definition of the ROC curve is based might
not be the ‘optimal’ one, in the sense that it might not be the classification rule based on
Y that provides the largest discriminatory capacity. We note that the optimality of the
classification rule is directly related to the concavity of the resulting ROC curve and refer
the reader to Fawcett (2006), Gneiting & Vogel (2018) and Pepe (2003, p. 71) for a more
extensive account on the importance of concave (also denoted in the literature as proper)
ROC curves.
3.3. ROC Curve and Related Indices Estimation
In what follows, let {yD¯i}nD¯i=1 and {yDj}nDj=1 be two independent random samples of test
outcomes from the nondiseased and diseased populations of size nD¯ and nD, respectively.
Statistical methods for estimating ROC curves have received wide attention in the
literature. Plenty of parametric, semi, and nonparametric estimators have been proposed,
both within frequentist and Bayesian paradigms. It would be an impossible task to cover, or
even mention, all methods available. We succinctly describe the main idea behind each class
of methods and further details can be found in the references provided. We give slightly
more details about the nonparametric methods, as they are more widely applicable.
A fully parametric approach estimates the constituent distribution functions parametri-
cally to arise at the induced ROC curve estimate. Let FD and FD¯ be parametrised in terms
of θD and θD¯, respectively, i.e., FD(y) = FD(y | θD) and FD¯(y) = FD¯(y | θD¯). Estimating
the parameters on the basis of test outcomes from each corresponding group, yields θ̂D and
θ̂D¯, and the resultant ROC estimate is
R̂OC(p) = 1− FD{F−1D¯ (1− p | θ̂D¯) | θ̂D}.
Typically, a normal distribution is assumed for both FD and FD¯, possibly after some trans-
formation of the YD and YD¯ scales (e.g., the logarithmic one or a Box–Cox type of trans-
formation). See Brownie et al. (1986) and Goddard & Hinberg (1990) for examples of this
approach.
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In a semiparametric setting, the most common approach for ROC curve estimation is
to assume a fully parametric form for the ROC curve, but making no assumptions about
the distributions of the test outcomes themselves. These type of approaches have also
been termed parametric distribution-free (Pepe 2000, Alonzo & Pepe 2002). The most
popular of these strategies is, perhaps, the binormal model, which postulates the existence
of some unspecified strictly increasing transformation H, such that H(YD) and H(YD¯)
follow a normal distribution. Specifically, and without loss of generality, if H is such that
H(YD) ∼ N(µ, σ2) and H(YD¯) ∼ N(0, 1), then the binormal ROC model is written as
ROC(p) = Φ{a+ bΦ−1(p)}, a = µ
σ
, b =
1
σ
,
where Φ(·) is the cumulative distribution function of the standard normal distribution.
The appropriateness of the binormality assumption was discussed, among others, by Swets
(1986) and Hanley (1996), who concluded that it provides a good approximation to a large
range of ROC curve shapes that occur in practice. Estimation of the binormal ROC curve
reduces to the problem of estimating a and b. The corresponding AUC has a closed-form
expression given by Φ(a/
√
1 + b2). Under the binormal model several estimation methods
have been proposed. The earliest approach is due to Dorfman & Alf (1969), but it was only
applicable to ordinal test results; later Metz et al. (1998) adapted it to the case of continuous
test results by using a strategy that relies on categorising the outcomes into a finite number
of categories and then applying the Dorfman and Alf procedure. Pepe (2000) and Alonzo &
Pepe (2002) suggest estimating the ROC curve by using procedures for fitting generalised
linear models to binary data (these procedures will be further detailed in Section 4). Zou &
Hall (2000) considered a method based on rank likelihood and Gu & Ghosal (2009) proposed
a Bayesian approach that also uses a rank-based likelihood. We also mention the work of
Cai & Moskowitz (2004) who developed a profile maximum likelihood approach.
Apart from parametric and semiparametric approaches, several authors have also de-
voted their attention to the development of nonparametric methods, which are more gen-
erally applicable. All nonparametric methods reviewed here rely on (flexibly) estimating
FD and FD¯ and plugging such estimates in Equation 3. The most popular and simplest
nonparametric method, due to Hsieh & Turnbull (1996), is based on estimating FD and FD¯
by their corresponding empirical distribution functions, that is,
F̂D(y) =
1
nD
nD∑
j=1
I(yDj ≤ y), F̂D¯(y) = 1nD¯
nD¯∑
i=1
I(yD¯i ≤ y).
Interestingly, the area under the empirical ROC curve is equal to the Mann–Whitney U
statistic (Bamber 1975)
ÂUC =
1
nDnD¯
nD∑
j=1
nD¯∑
i=1
{
I (yDj > yD¯i) +
1
2
I (yDj = yD¯i)
}
.
As it is clear from its definition, the empirical ROC curve is an increasing step function,
which can be quite jagged, especially for small sample sizes and, as a consequence, might
be unappealing in practice. To overcome the lack of smoothness of the empirical estimator,
kernel-based methods for estimating the ROC curve have been developed. The earliest
approach is due to Zou et al. (1997), who suggested estimating the density function in each
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population using kernel density estimates. Specifically,
f̂D(y) =
1
nDhD
nD∑
j=1
k
(
y − yDj
hD
)
, f̂D¯(y) =
1
nD¯hD¯
nD¯∑
i=1
k
(
y − yD¯i
hD¯
)
,
where fD (fD¯) corresponds to the density associated to FD (FD¯), k(·) is the kernel function,
and hD (hD¯) is the bandwidth or smoothing parameter. The kernel considered was the
biweight and the corresponding distribution function estimates, F̂D and F̂D¯, were obtained
by numerical integration. In a follow-up work, Zou et al. (1998) suggested the use of the
normal kernel and, in such case, the estimates of the distribution functions can be written
as
F̂D(y) =
1
nD
nD∑
j=1
Φ
(
y − yDj
hD
)
, F̂D¯(y) =
1
nD¯
nD¯∑
i=1
Φ
(
y − yD¯i
hD¯
)
.
Still for the normal kernel, Lloyd (1998) has shown that the resulting estimate of the AUC
has the following form
ÂUC =
1
nDnD¯
nD∑
j=1
nD¯∑
i=1
Φ
 yDj − yD¯i√
h2D + h
2
D¯
 .
The bandwidth, which controls the amount of smoothing and whose selection is critical
to the performance of the estimator, was based on Silverman’s rule of thumb (Silverman
1986, p. 48), which is optimal for data that are approximately bell-shaped distributed.
Alternatively, the bandwidth can also be selected by least squares cross-validation; although
this has not been proposed by the authors, it works quite well in practice for density
estimation. The fact that the bandwidth proposed by Zou et al. (1997) is not optimal for
the ROC curve, because the latter depends on the distribution functions, and optimality for
estimating density functions does not carry over the distribution functions, prompted Lloyd
(1998) and Zhou & Harezlak (2002), among other authors, to improve the above estimator
by obtaining asymptotically optimal estimates for FD and FD¯.
To finish this section, we turn our attention to Bayesian approaches and start with
the nonparametric method of Erkanli et al. (2006), which models the distribution of test
outcomes in each group via a Dirichlet process mixture of normal distributions (Escobar &
West 1995), that is,
FD(y) =
∫
Φ(y | µ, σ2)dG(µ, σ2), G ∼ DP(αD, G∗D(µ, σ2)), 7.
with the distribution function in the nondiseased group following analogously. Here GD ∼
DP(αD, G
∗
D) is used to denote that the mixing distribution GD follows a Dirichlet process
(DP) prior (Ferguson 1973) with centring distribution G∗D, for which E(GD) = G
∗
D and
which encapsulates any prior knowledge that might be known about GD, and precision
parameter αD, which controls the variability of GD around G
∗
D. Larger values of αD result
in realisations GD that are closer to G
∗
D. Unarguably, the most useful definition of the DP
is its constructive definition due to Sethuraman (1994), which postulates that GD can be
written as
GD(·) =
∞∑
l=1
ωDlδ(µDl,σ2Dl)
(·),
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where δa denotes a point mass at a, (µDl, σ
2
Dl)
iid∼ G∗D(µ, σ2), and the weights follow the
so-called stick-breaking construction: ωD1 = vD1, ωDl = vDl
∏
m<l(1−vDm), for l ≥ 2, and
vDl ∼ Beta(1, αD), for l ≥ 1. Under Sethuraman’s representation, the distribution function
in Equation 7 can be written as an infinite location-scale mixture of normal distributions,
i.e.,
FD(y) =
∞∑
l=1
ωDlΦ(y | µDl, σ2Dl). 8.
For the ease of posterior inference, a conjugate centring distribution is usually specified,
i.e., G∗D ≡ N(µ | mD, SD)Γ(σ−2 | aD, bD). A blocked Gibbs sampler (Ishwaran & James
2002), which relies on truncating the infinite mixture in Equation 8 to a finite number of
components, say LD, can then be used for conducting posterior inference, thus obtaining
posterior samples of the weights, components’ means and variances. Note that LD is not
the number of components one expects to observe in the data but an upper bound on it.
At iteration s of the Gibbs sampler procedure, the ROC curve is computed as
ROC(s)(p) = 1− F (s)D {F−1(s)D¯ (1− p)}, s = 1, . . . , S,
F
(s)
D (y) =
LD∑
l=1
ω
(s)
DlΦ(y | µ(s)Dl , σ2(s)Dl ), F (s)D¯ (y) =
LD¯∑
l=1
ω
(s)
D¯l
Φ(y | µ(s)
D¯l
, σ
2(s)
D¯l
).
As shown by the authors, the AUC admits the following closed-form expression
AUC(s) =
LD¯∑
k=1
LD∑
l=1
ω
(s)
D¯k
ω
(s)
DlΦ
 a(s)kl√
1 + b
2(s)
kl
 , a(s)kl = µ(s)Dl − µ(s)D¯k
σ
(s)
Dl
, b
(s)
kl =
σ
(s)
D¯k
σ
(s)
Dl
. 9.
At the end of the sampling procedure an ensemble composed of S ROC curves/AUCs is
available. The average of the ensemble is used as a point estimate and the variation in the
ensemble is used to construct credible bands/intervals.
A somehow related approach is the Bayesian bootstrap (BB) ROC curve estimation
procedure developed by Gu et al. (2008), which assumes that FD and FD¯ follow a Dirichlet
process prior, rather than a Dirichlet process mixture as in the previous approach, i.e.,
{yDj}nDj=1, | FD ∼ FD, FD ∼ DP(αD, G∗D),
{yD¯i}nD¯i=1 | FD¯ ∼ FD¯, FD¯ ∼ DP(αD¯, G∗¯D),
where by a slight abuse of notation we are also using here the same DP parameters’. From
the conjugacy property of the DP (Ferguson 1973), which ensures that
FD | {yDj}nDj=1 ∼ DP
(
αD + nD,
αD
αD + nD
G∗D +
1
αD + nD
nD∑
j=1
δyDj
)
, 10.
it is clear that considering the noninformative limit of the DP, by letting αD → 0 and
αD¯ → 0, simplifies drastically the computational effort, as one does not even need to
specify the centring distributions G∗D and G
∗¯
D (an equivalent to Equation 10 holds for
the nondiseased population). All that is needed is to generate from the uniform distri-
bution over the simplex, which is equivalent to generating from a Dirichlet distribution
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with all parameters equal to one. The BB estimator of the ROC curve relies on a two-
step procedure that makes use of the representation of the ROC curve as the distribu-
tion function of the diseased placement variable UD. Specifically, as shown by the au-
thors, it is only needed to 1) impute the variable UD = 1 − FD¯(YD) by plugging-in the
survival function of YD¯, generated from the BB resampling distribution given test out-
comes (yD¯1, . . . , yD¯nD¯ ), and 2) compute the distribution function of UD based on the BB
resample distribution to form one (of, say, S) realisation of the ROC curve. In fact,
Step 1 is as simple as computing U
(s)
Dj =
∑nD¯
i=1 q
(s)
1i I(yD¯i ≥ yDj), j = 1, . . . , nD, and
where (q
(s)
11 , . . . , q
(s)
1nD¯
) ∼ Dirichlet(nD¯; 1, . . . , 1). In Step 2, we only need to calculate
ROC(s)(p) =
∑nD
j=1 q
(s)
2j I(U
(s)
Dj ≤ p), with (q(s)21 , . . . , q(s)2nD ) ∼ Dirichlet(nD; 1, . . . , 1). The
AUC can also be expressed in closed form as AUC(s) = 1−∑nDj=1 q(s)2j U (s)Dj .
Still within a Bayesian nonparametric framework, we mention the approach of Branscum
et al. (2008), which is based on a different nonparametric prior, namely, a mixture of finite
Polya trees, for modelling FD and FD¯. At last, for an overview article entirely dedicated to
ROC curve estimation, we refer to Gonc¸alves et al. (2014).
Concerning the estimation of the Youden index and/or associated optimal threshold,
for all approaches that rely on estimating the distribution functions of test outcomes, they
can be obtained by simply plugging the corresponding estimates of FD and FD¯ in Equation
5. For the binormal model, where it is not assumed an explicit distribution for the test
outcomes, Equation 6 should instead be used. For a detailed comparison among different
methods (namely, empirical, kernel, and a pararametric one assuming normality on the
original scale or after a Box–Cox transformation), we refer the reader to the article by
Fluss et al. (2005).
3.4. Illustration
We now illustrate the methods described in the previous section with the HOMA-IR dataset.
Recall that we seek to assess the accuracy of the HOMA-IR levels when predicting the
presence of cardio-metabolic risk. Here we stratify the analysis by gender but disregard the
age effect (i.e., HOMA-IR levels were pooled together regardless the age of the individuals).
As we will be using both the kernel-based approach and the Dirichlet process mixture model
with a normal kernel, the logarithm of HOMA-IR levels was considered. Figure 1 in the
Supplementary Materials shows the estimated densities, by gender and in each population
(individuals with and without cardio-metabolic risk), under the Dirichlet process mixture
of normals model and the (normal) kernel method with bandwidth selected by Silverman’s
rule of thumb, and we can appreciate that both are very similar and follow the histograms
of HOMA-IR levels quite closely. The estimated ROC curves using the four nonparametric
methods described in the previous section are depicted in Figure 3. All methods produced
very similar ROC curves. In Figure 2 of the Supplementary Materials we depict the same
ROC curves but without the confidence/credible bands, so that the comparison between
point estimates is clearer. The corresponding AUCs are reported in Table 2 and they are,
both for men and women, close to 0.70, revealing a mild accuracy of HOMA-IR levels for
predicting cardio-metabolic risk. This comes as no surprise as Figure 1 already evidenced
a quite considerable overlap of HOMA-IR levels in the two populations. Table 1 of the
Supplementary Materials presents the Youden index and corresponding optimal HOMA-
IR thresholds estimates that can be used to detect, in practice, individuals with higher
cardio-metabolic risk.
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Figure 3
Estimated ROC curves. The continuous lines correspond to point estimates and the shaded regions to the 95% pointwise
credible/confidence bands. Here BB stands for the Bayesian bootstrap method (Gu et al. 2008) and DPM for the Dirichlet
process mixture of normals model (Erkanli et al. 2006).
Table 2 AUC point estimates and 95% credible/confidence intervals. Here BB stands
for the Bayesian bootstrap method (Gu et al. 2008) and DPM for the Dirichlet process
mixture of normals model (Erkanli et al. 2006).
AUC
Approach Women Men
Empirical 0.691 (0.634, 0.736) 0.695 (0.647, 0.741)
Kernel 0.683 (0.629, 0.728) 0.687 (0.641, 0.733)
DPM 0.685 (0.631, 0.736) 0.691 (0.643, 0.736)
BB 0.691 (0.635, 0.743) 0.695 (0.646, 0.740)
4. ROC CURVES AND COVARIATES
4.1. Motivation
The definition of ROC curve given in Equation 3 implicitly assumes that both the diseased
and nondiseased populations are homogeneous, at least, with regard to the performance of
the test. However, this is rarely the case in practice. For instance, coming back to our
motivating example, Figure 4 shows the densities of log HOMA-IR levels conditional on the
age and gender of the subjects. It can be noticed that, especially for women, the overlap
between the two distributions of log HOMA-IR levels changes with age, and thus we expect
the accuracy of log HOMA-IR levels to vary across age as well. This illustrates that, quite
often, the distribution of test outcomes, either in the nondiseased or diseased population,
or in both, is likely to vary with covariates. Examples of such covariates include subject-
specific characteristics or different test settings. We note in passing that this does not
necessarily mean covariates affecting the discriminatory capacity of the test. In particular,
the distributions of test outcomes might experience a shift for different covariate values
but their overlap might remain the same, case in which the accuracy of the test does not
change, but still the thresholds used for defining a positive result will be covariate-specific
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(for further details we refer to Pepe 2003, Chapter 6, Pardo Ferna´ndez et al. 2014, and
Ina´cio de Carvalho & Rodr´ıguez-A´lvarez 2018).
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Figure 4
Estimated density functions, obtained using a single-weights dependent Dirichlet process mixture of normals model, of log
HOMA-IR levels in the diseased (dotted line, orange) and nondiseased (solid line, blue) populations, conditional on age
and gender.
4.2. Notation and Definitions
Let us now assume that along with YD and YD¯, covariate vectors XD and XD¯ are also
available. For ease of notation, we assume that the covariates of interest are the same in
both populations, although this is not always necessarily the case (e.g., disease stage is,
obviously, a disease-specific covariate).
As a natural extension of the ROC curve, the conditional or covariate-specific ROC
curve, given a covariate value x, is defined as
ROC(p | x) = 1− FD{F−1D¯ (1− p | x) | x}, 0 ≤ p ≤ 1, 11.
where FD(y | x) = Pr(YD ≤ y | XD = x) denotes the conditional distribution function in
the diseased group, with FD¯(y | x) being defined similarly. The covariate-specific counter-
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parts of the AUC and YI are given by
AUC(x) =
∫ 1
0
ROC(p | x)dp 12.
YI(x) = max
c
{FD¯(c | x)− FD(c | x)} 13.
= max
p
{ROC(p | x)− p} 14.
For each value of x we might obtain a different ROC curve (AUC and/or Youden index)
and, therefore, also a possible different accuracy. Understanding the influence of covariates
on the accuracy of a diagnostic test will help in determining the optimal and suboptimal
populations where to perform the diagnostic tests on.
4.3. Covariate-specific ROC curve estimation
Approaches to estimation of the covariate-specific ROC curve can be broadly divided in
two categories (Pepe 1998). Induced methodologies model the distribution of test outcomes
in the diseased and nondiseased populations separately and then compute the induced
ROC curve. On the other hand, direct methodologies assume a regression model directly
on the covariate-specific ROC curve. In what follows, we now let {(xD¯i, yD¯i)}nD¯i=1 and
{(xDj , yDj)}nDj=1 be two independent random samples of covariates and test outcomes from
the nondiseased and diseased populations of size nD¯ and nD, respectively. Further, for all
i = 1, . . . , nD¯ and j = 1, . . . , nD, let xD¯i = (xD¯i,1, . . . , xD¯i,q)
′ and xDj = (xDj,1, . . . , xDj,q)′
be q−dimensional vectors of covariates, which can be either continuous or categorical.
4.3.1. Induced methodology. For clarity in the presentation, within the induced methodol-
ogy, we distinguish between two types of approaches. Both aim at estimating the constituent
components of the covariate-specific ROC curve, i.e., the conditional distribution of test re-
sults in the diseased and nondiseased populations (see Equation 11). However, whereas
the first set of methods do it through the specification of a location-scale regression model
for the test outcomes in each population, the second set focus on directly modelling the
conditional distributions.
We start by presenting the first mentioned induced approach. Specifically, the rela-
tionship between covariates and test outcomes in each population is given by location-scale
regression models
YD = µD(XD) + σD(XD)εD, YD¯ = µD¯(XD¯) + σD¯(XD¯)εD¯, 15.
where µD(x) = E(YD | XD = x) and σ2D = var(YD | XD = x) are, respectively, the
conditional mean and variance of YD given XD = x, with µD¯ and σ
2
D¯ being analogously
defined. The error terms εD and εD¯ are assumed to be independent of each other and
of the covariates, with zero mean, unit variance, and distribution function FεD and FεD¯ ,
respectively. Given the independence between the error and the covariates in the location-
scale regression models in Equation 15, it is easy to show that
FD(y | x) = FεD
(
y − µD(x)
σD(x)
)
, FD¯(y | x) = FεD¯
(
y − µD¯(x)
σD¯(x)
)
.
An analogous relationship can be established between the conditional quantile function of
test outcomes given the covariates and the quantile function of the error terms, namely
F−1D (p | x) = µD(x) + σD(x)F−1εD (p), F−1D¯ (p | x) = µD¯(x) + σD¯(x)F−1εD¯ (p).
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The covariate-specific ROC curve, for a given covariate value x, can therefore be expressed
as
ROC(p | x) = 1− FεD
{
µD¯(x)− µD(x)
σD(x)
+
σD¯(x)
σD(x)
F−1εD¯ (1− p)
}
, 0 ≤ p ≤ 1.
This formulation allows expressing the covariate-specific ROC curve in terms of the dis-
tribution and quantile functions of the regression errors, which are not conditional, thus
reducing the computational burden.
Thus far we have described this form of induced ROC methodology in its most general
form. Particular cases have been addressed in the literature. In particular, Faraggi (2003)
assumed a normal linear homoscedastic model in each population, that is
µD(x) = x˜
′βD, σD(x) = σD, FεD (·) = Φ(·),
with x˜′ = (1,x′) and βD = (βD0, . . . , βDq)
′ is a (q + 1)−dimensional vector of (unknown)
regression coefficients. All quantities are analogously defined for the nondiseased popula-
tion. Estimates of the regression coefficients βD and βD¯ are obtained by ordinary least
squares on the basis of the samples {(xDj , yDj)}nDj=1 and {(xD¯i, yD¯i)}nD¯i=1, respectively. The
variances are then straightforwardly estimated as
σ̂2D =
∑nD
j=1(yDj − x˜′Djβ̂D)2
nD − q − 1 , σ̂
2
D¯ =
∑nD¯
i=1(yD¯i − x˜′¯Diβ̂D¯)2
nD¯ − q − 1
.
The corresponding covariate-specific ROC curve is given by
R̂OC(p | x) = 1− Φ{a(x) + bΦ−1(1− p)}, a(x) = x˜′ (β̂D¯ − β̂D)
σ̂D
, b =
σ̂D¯
σ̂D
.
As for the binormal ROC curve in the no-covariate case, the AUC under this model is given
by Φ(−a(x)/√1 + b2).
Alternatively, and less restrictive, Pepe (1998) suggests to estimate the distribution
function of the errors in each population by the corresponding empirical distribution func-
tion of the estimated standardised residuals. Note that in the original paper the same
distribution was assumed in both populations, but we are presenting here the more general
case in which each population has its own distribution, i.e.,
F̂εD (y) =
1
nD
nD∑
j=1
I(ε̂Dj ≤ y), ε̂Dj = yDj − x˜
′
Djβ̂D
σ̂D
,
with F̂εD¯ (y) and ε̂D¯i, i = 1, . . . , nD¯, are defined in a similar fashion. The covariate-specific
ROC curve is finally computed in an analogous way as for the method of Faraggi (2003) as
R̂OC(p | x) = 1− F̂εD{a(x) + bF̂−1εD¯ (1− p)}, 0 ≤ p ≤ 1.
The covariate-specific AUC also admits a closed-form expression which can be regarded as
a covariate-specific Mann–Whitney type of statistic, that is,
ÂUC(x) =
1
nDnD¯
nD∑
j=1
nD¯∑
i=1
I{µ̂D¯(x) + σ̂D¯ ε̂D¯i ≤ µ̂D(x) + σ̂D ε̂Dj}. 16.
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Still in a semiparametric context, Zheng & Heagerty (2004) proposed an estimator for the
covariate-specific ROC curve in which the distribution of the error terms is unknown and
allowed to depend on covariates (and so, strictly speaking, the underlying models for the
test outcomes are no longer location-scale regression models) but, as in the previous two
approaches, the effect of the covariates on the conditional means and variances is modelled
parametrically. In a Bayesian context, Rodr´ıguez & Mart´ınez (2014) proposed a semipara-
metric model, where the (marginal) error terms are assumed to follow a Student-t distri-
bution and the conditional mean and variance functions are modelled nonparametrically
through Gaussian process priors.
Within a nonparametric frequentist perspective, Yao et al. (2010), Gonza´lez-Manteiga
et al. (2011), and Rodr´ıguez-A´lvarez et al. (2011b) all proposed a kernel-based approach
to estimate the mean and variance functions in Equation 15 but, as proposed by these
authors, the method can only deal with one continuous covariate. Both the regression
and the variance functions are estimated using local polynomial kernel smoothers (Fan &
Gijbels 1996). Estimation proceeds in a sequential manner: 1) the regression functions in the
diseased and nondiseased populations are estimated first on the basis of {(xDj , yDj)}nDj=1
and {(xD¯i, yD¯i)}nD¯i=1, respectively, and 2) the variance function is estimated next on the
basis of the samples {(xDj , [yDj − µ̂D(xDj)]2)}nDj=1 and {(xD¯i, [yD¯i − µ̂D¯(xD¯i)]2)}nD¯i=1. Both
steps involve the selection of a smoothing parameter and that can be done, for instance,
via least squares cross-validation. Once estimates of the mean and variance functions are
available, the standardised residuals can be calculated and, as in Pepe’s method, their
empirical distribution function is used to estimate the distribution of the error terms. The
covariate-specific AUC can also be written in the form of Equation 16, with the mean and
variance functions replaced by their corresponding kernel-based counterparts. Because the
estimator of the conditional ROC curve is based on the emprirical distribution function (of
the standardised residuals), the resulting estimator is not smooth and, in order to overcome
this drawback, Gonza´lez-Manteiga et al. (2011) also proposed an estimator that makes use
of a further bandwidth and does the convolution with a continuous kernel, namely
R̂OCh(p | x) = 1−
∫
F̂εD
(
a(x) + F̂−1εD¯ (1− p+ hu)b(x)
)
k(u)du,
where a(x) =
µ̂D¯(x)−µ̂D(x)
σ̂D(x)
, b(x) =
σ̂D¯(x)
σ̂D(x)
, and k(·) is a kernel function. Note that when
h = 0 the non-smooth estimator is recovered.
We now briefly detail the approach of Ina´cio de Carvalho et al. (2013) which, by op-
position to the previous approaches, is based on directly modelling the conditional distri-
bution function of test outcomes in the diseased and nondiseased populations, allowing it
to smoothly change as a function of the covariates. Specifically, the authors use a single-
weights linear dependent Dirichlet process mixture of normals to model the conditional
distribution in each population
FD(y | x) =
∫
Φ(y | µ(x,β), σ2)dGD(β, σ2), GD ∼ DP(αD, G∗D(β, σ2)),
with the conditional distribution function in the nondiseased population following in an
analogous manner. This model can be regarded as an extension to the conditional case
of the method of Erkanli et al. (2006). As in the no-covariate case, using Sethuraman’s
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representation, the conditional distribution can be expressed as
FD(y | x) =
∞∑
l=1
ωDlΦ
(
y | µ(x,βDl), σ2Dl
)
, 17.
with the weights matching those from the stick-breaking construction as specified in
Erkanli’s model. Notice that the only difference between Equations 8 and 17 is that now the
mean of each component depends on covariates. Regarding the specification of the com-
ponents’ means, it has been recommended (see Ina´cio de Carvalho & Rodr´ıguez-A´lvarez
2018 for more details) to use a flexible formulation, so that a large number of (conditional)
density shapes’ are well-approximated. In particular, cubic B-splines basis functions are
used for continuous covariates and, as a result, we write
µ(x,βDl) = z
′
DβDl, l ≥ 1, j = 1, . . . , nD,
where zD is the vector containing the intercept, the cubic B-splines basis representation of
the continuous covariates, the categorical covariates (if any), and their interaction(s) with
the smoothed continuous covariate(s) (if believed to exist). Also, βDl collects, for the lth
component, the regression coefficients associated with the aforementioned covariate vec-
tor. The regression coefficients and variances associated with each component are sampled
from a conjugate centring distribution (βDl, σ
−2
Dl )
iid∼ N(mD,SD)Γ(aD, bD) and, as in the
unconditional case, the blocked Gibbs sampler is used to simulate draws from the posterior
distribution. At iteration s of the Gibbs sampler procedure, the covariate-specific ROC
curve is computed as
ROC(s)(p | x) = 1− F (s)D {F−1(s)D¯ (1− p | x) | x}, s = 1, . . . , S,
F
(s)
D (y | x) =
LD∑
l=1
ω
(s)
DlΦ(y | z′Dβ(s)Dl , σ2(s)Dl ), F (s)D¯ (y | x) =
LD¯∑
l=1
ω
(s)
D¯l
Φ(y | z′¯Dβ(s)D¯l , σ
2(s)
D¯l
).
The covariate-specific AUC admits exactly the same closed form expression as in Equation
9, with the obvious difference that the components’ means are covariate-dependent, i.e., we
now have
a
(s)
kl (x) =
µ(x,β
(s)
Dl )− µ(x,β(s)D¯k)
σ
(s)
Dl
.
Point and interval estimates for the covariate-specific ROC curve and AUC can be obtained
from the corresponding ensembles of posterior realisations.
Another estimator for the conditional ROC curve that also directly models the condi-
tional distribution of test outcomes, but based on kernel methods, was proposed by Lo´pez-de
Ullibarri et al. (2008).
In what concerns estimation of the covariate-specific Youden index and/or associated
threshold, because all induced approaches, in a more or less direct way, provide an estimate
of the conditional distribution function of the test outcomes in each population, these can
be plugged in the definition in Equation 13, so that estimates of these quantities can be
obtained. We also mention here the work by Xu et al. (2014), where the authors propose
an approach that directly estimates the covariate-specific YI and threshold value without
the need of first estimating the conditional distribution functions.
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4.3.2. Direct methodology. In contrast to the induced approach, in the direct methodology
the effect of the covariates is directly evaluated on the ROC curve, with its general form
given by the following regression model
ROC(p | x) = g{µ(x) + h0(p)}, 0 ≤ p ≤ 1, 18.
where µ(x) collects the effects of the covariates on the ROC curve, h0(p) is an unknown
monotonic increasing function of the FPF related to the shape of the ROC curve and g is
the inverse of the link function. Unlike in standard regression analysis, the response variable
of the model presented in Equation 18 is not directly observable. However, note that the
covariate-specific ROC curve can be re-expressed as
ROC(p | x) = 1− FD{F−1D¯ (1− p | x) | x}
= 1− Pr{YD ≤ F−1D¯ (1− p | x) | XD = x}
= Pr{1− FD¯(YD | x) < p | XD = x}
= E[I(1− FD¯(YD | x) < p) | XD = x], 19.
and, in particular, as highlighted by Equation 19, it can be interpreted as the conditional
expectation of the binary variable I(1−FD¯(YD | x) < p) and, therefore, the ROC regression
model in Equation 18 can be viewed as a regression model for I(1−FD¯(YD | x) < p). Note
that 1− FD¯(YD | XD = x) is nothing more than the conditional diseased placement value,
that is, a covariate-specific version of the UD variable introduced in Section 3.
Different estimation proposals, which differ in the assumptions made about g, µ, and
h0, have been suggested in the literature. In Pepe (2000) and Alonzo & Pepe (2002), g is
assumed to be known (e.g., g(·) = Φ(·)), the effect of the covariates on the conditional ROC
curve is assumed to be linear, i.e., µ(x) = x′β, and the baseline function h0 is assumed
to have a parametric form given by h0(p) =
∑K
k=1 αkhk(p), where α = (α1, . . . , αK)
′ is a
vector of unknown parameters and h(p) = (h1(p), . . . , hK(p)) are known functions. Note
that the binormal model for the (unconditional) ROC curve arises when no covariates are
considered and for g(·) = Φ(·), h1(p) = 1, and h2(p) = Φ−1(p). Cai & Pepe (2002) and
Cai (2004) studied a more flexible model by leaving h0 completely unspecified, but the
function µ is still modelled in a linear way and g is also considered to be known. In general,
models like those in Equation 18 with parametric specifications for µ define the so-called
class of ROC-GLMs due to the similarities with generalised linear models (Pepe 2000). In
contrast to the previous cited works, Lin et al. (2012) developed a semiparametric model
where both the link and baseline functions are completely unknown and µ is assumed to
have a parametric form. Finally, Rodr´ıguez-A´lvarez et al. (2011a) assumes that g is known
but an additive smooth structure is assumed for µ(x), i.e., µ(x) = β +
∑q
k=1 fk(xk), where
f1, . . . , fq are unknown nonparametric functions and h0 also remains unspecified.
Regardless of whether the specification in Equation 18 involves a generalised linear
or additive model structure, the estimation process is similar and can be described as
given in the following steps. First, one must choose a set of FPFs, say 0 ≤ pl ≤ 1 for
l = 1, . . . , nP , where the covariate-specific ROC curve will be evaluated. Second, an estimate
of FD¯(· | x), say F̂D¯(· | x), on the basis of the sample {(xD¯i, yD¯i)}nD¯i=1, must be obtained.
Third, one should calculate the estimated placement value for each disease observation
1− F̂D¯(yDj | xDj), for j = 1, . . . , nD. The fourth step involves the calculation of the binary
indicators I(1− F̂D¯(yDj | xDj) ≤ pl), for j = 1, . . . , nD and l = 1, . . . , nP . Lastly, in fifth,
the model g(µ(x) + h0(p)) is fitted as a regression model for binary data with indicators
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I(1 − F̂D¯(yDj | xDj) ≤ pl) as the response variable and covariates xDj and h(pl) (when
h0 is modelled parametrically) or pl (when h0 is left unspecified), for j = 1, . . . , nD and
l = 1, . . . , nP . We note that the above algorithm does not apply for the estimation of the
proposals described in Cai & Pepe (2002), Cai (2004), and Lin et al. (2012). For conciseness
we do not present here the details of their approaches, but refer the readers to the respective
articles.
Regarding the estimation of the conditional AUC within the direct methodology, the
obvious way is to simply plug-in an estimate for the conditional ROC curve in Equation 12,
and approximate the integral using numerical integration methods. However, this approach
might not be the most efficient one, and several methods to directly estimate AUC(x) have
been proposed in the literature. We mention here the articles by Dodd & Pepe (2003b,a) and
Cai & Dodd (2008), where semiparametric regression models for the conditional (partial)
AUC are proposed. For the Youden index (and associated threshold value), to the best of
our knowledge, no direct estimators have been proposed. Estimation, in this case, requires
making use of Equation 14, with ROC(p | x) being replaced by its estimate. Note that, once
we obtain the (conditional) FPF at which the maximum of 14 is attained, an estimate of
the associated conditional threshold value can be obtained using the estimator of FD¯(· | x)
needed in the second step of the above described algorithm.
4.4. Covariate-adjusted ROC curve
The covariate-specific ROC curve and associated AUC and YI assess the accuracy of the
test for specific covariate values. It would, however, be useful to have a global summary
measure that also takes covariate information into account. The covariate-adjusted ROC
(AROC) curve proposed by Janes & Pepe (2009) is exactly one of such measures. It is
defined as
AROC(p) =
∫
ROC(p | x)dHD(x),
where HD(x) = Pr(XD ≤ x) is the distribution function of XD. That is, the AROC curve is
a weighted average of covariate-specific ROC curves, weighted according to the distribution
of the covariates in the diseased group. As shown by the authors, the AROC curve can also
be expressed as
AROC(p) = Pr{YD > F−1D¯ (1− p | XD)} = Pr{1− FD¯(YD | XD) ≤ p},
emphasising that the AROC curve at a FPF of p is the overall TPF when the thresholds used
for defining a positive test result are covariate-specific and chosen to ensure that the FPF is
p in each subpopulation defined by the covariate values. We refer to Janes & Pepe (2009),
Rodr´ıguez-A´lvarez et al. (2011b), and Ina´cio de Carvalho & Rodr´ıguez-A´lvarez (2018) for
the different estimation methods available for the ROC curve.
A natural question to ask is when to use the covariate-specific ROC curve and the
covariate-adjusted ROC curve. Very briefly, and without going into details, when the
accuracy of the test does change with the covariates (i.e., when the separation between the
distributions of test outcomes changes for different covariate levels), the covariate-specific
ROC curve should be the primary tool to be used. On the other hand, if the distributions of
the test outcomes change with covariates but not the accuracy of the test (i.e., if the overlap
between the distributions of test outcomes remains the same for different covariate levels),
then the covariate-adjusted ROC curve, which in this case corresponds to the common
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covariate-specific ROC curve, should be instead reported. For a lengthy discussion of this
point, see Pepe (2003, Chapter 6), Janes & Pepe (2008a), Janes & Pepe (2008b), and
Ina´cio de Carvalho & Rodr´ıguez-A´lvarez (2018). Also, for a recent overview article focusing
exclusively on ROC curves and covariates, we refer to Pardo Ferna´ndez et al. (2014).
4.5. Illustration
We revisit our example dataset and the aim now is to assess the effect of age and gender
on the ability of HOMA-IR levels for predicting cardio metabolic-risk. In Figure 5 (top) we
present several ROC curves, obtained using the induced Bayesian nonparametric approach
of Ina´cio de Carvalho et al. (2013), associated with different ages, for both men and women.
While there is no substantial variation in the shape of the ROC curves in men, there is
considerable differences for women (as already expectable given the conditional densities in
Figure 4). To get deeper insight, in Figure 5 (bottom) we depict the covariate-specific AUC
for ages between 27 and 83 years old, which roughly correspond to the age interval where
the two populations, for both men and women, had observations. Results are also shown
for the kernel-based approach of Rodr´ıguez-A´lvarez et al. (2011b), with the analysis in men
and women conducted separately. It is also important to mention that for the approach of
Ina´cio de Carvalho et al. (2013) an interaction between age and gender was included. As
foreseen, there is essentially no dynamic for the age-specific AUC in men. On the other
hand, for women, the results suggest a decrease in the accuracy of HOMA-IR levels as age
increases. Additionally, Figure 3 in the Supplementary Materials shows the age/gender-
specific Youden index and associated age/gender-specific HOMA-IR optimal thresholds.
5. ROC CURVES AND TIME (AND COVARIATES)
Up to now we have been concerned about diagnosis. Yet, depending on the clinical cir-
cumstances, the aim and interest might involve prognosis rather than diagnosis. The main
difference between diagnostic and prognostic settings is that the latter involves a time di-
mension. More specifically, in a prognostic setting the test outcome is measured at a given
time (usually at baseline) and disease onset may occur at any time thereafter. As such, in
prognosis, the true positive and negative fractions, and by consequence the ROC curve, are
time dependent and may be calculated for different times.
Here we only attempt to cover the main concepts, pointing the reader to the appropriate
references about the estimation approaches. With regard to notation, as before, let Y be
a continuous random variable denoting the test outcome and, additionally, let T , also a
continuous random variable, denotes the time to disease onset. Further, let D(t) be the
disease status at time t, with D(t) = 1 indicating that disease onset is prior to time t,
and D(t) = 0 otherwise. Heagerty & Zheng (2005) proposed three definitions of the time-
dependent true positive and negative fractions (which give rise to different definitions of
the time-dependent ROC curve), namely, the cumulative TPF and dynamic TNF, the
incident TPF and dynamic TNF, and the incident TPF and static TNF. These different
definitions differ mainly in how disease and nondisease status are defined. We focus on the
cumulative/dynamic definition, where a diseased subject is any subject diagnosed between
baseline (assumed to be the time t = 0) and time t and a nondiseased subject is any
individual free of disease at time t. From a practical point of view it has been argued
(Blanche et al. 2013, Rodr´ıguez-A´lvarez et al. 2016) that this is the most relevant definition,
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Figure 5
Estimated age/gender-specific ROC curves using the approach of Ina´cio de Carvalho et al. (2013) (top). Estimated
age/gender-specific AUC. The continuous lines correspond to point estimates and the shaded regions correspond to the
95% pointwise credible/confidence bands. Here BNP stands for the Bayesian nonparametric method of Ina´cio de Carvalho
et al. (2013) and Kernel for the approach of Rodr´ıguez-A´lvarez et al. (2011b).
as clinicians often want to predict disease onset within a window of time rather than at
a specific time (as in the incident TPF) and the goal is also to distinguish nondiseased
subjects at the end of such time window and not at a later pre-specified time (as implied
by the static FNF).
For a threshold c and a given time t, Heagerty et al. (2000) defined the cumulative true
positive fraction TPF(c,t) and the dynamic true negative fraction TNF(c, t) by
TPF(c, t) = Pr(Y ≥ c | D(t) = 1) = Pr(Y ≥ c | T ≤ t),
TNF(c, t) = Pr(Y < c | D(t) = 0) = Pr(Y < c | T > t).
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In words, the cumulative TPF is the probability that a subject has a test outcome equal
or greater than c among those individuals who developed the disease by time t, whereas
the dynamic TNF is the probability that an individual has a test result less than c among
those who are disease free beyond that same time t. Under this definition, the sets of
diseased and nondiseased subjects are changing over time and each individual might be in
the nondiseased group at an earlier time and then in the diseased group at later times.
The corresponding time-dependent ROC curve is defined as the plot of FPF(c, t) versus
TPF(c, t) for all values of c, that is, {(FPF(c, t),TPF(c, t) : c ∈ R}. In analogy to Equation
3, the time-dependent ROC curve can also be written as
ROC(p, t) = TPF{FPF−1(p, t), t}, 0 ≤ p ≤ 1,
where FPF−1(p, t) = inf{c ∈ R : FPF(c, t) ≤ p}. The AUC has been the preferred summary
measure in the time-dependent context
AUC(t) =
∫ 1
0
ROC(p, t)dp,
and it is worth noting that it also accepts a probabilistic intepretation
AUC(t) = Pr(Yl > Ym | Dl(t) = 1, Dm(t) = 0) = Pr(Yl > Ym | Tl ≤ t, Tm > t),
where l and m denote the indices of two randomly chosen subjects.
When it comes to estimating time-dependent ROC curves, one of the challenges is the
(potential) presence of censoring. In practice, some subjects may be lost during the follow-
up period, thus introducing right-censoring, and making it impossible to know if disease
onset has happened before the time point t for such subjects. Ignoring censoring might lead
to biased estimates of the true positive and negative fractions. To address this issue, several
approaches have been proposed to estimate the cumulative TPF, the dynamic TNF, and the
corresponding ROC curve. The first proposal is due to Heagerty et al. (2000) who developed
estimators based on the Bayes’ theorem and the Kaplan–Meier estimator of the survival
function. The fact that this approach does not necessarily yield monotone true positive and
negative fractions led the authors to propose an alternative approach based on a nearest
neighbour estimator of the bivariate distribution of the test result and time to disease onset.
Later Chambless & Diao (2006) proposed two alternative estimation methods for the TPF
and TNF, one that deals with censoring by conditioning on the observed disease onset
times as in the Kaplan-Meier estimator and another one that makes use of a Cox model.
In turn, Uno et al. (2007) and Hung & Chiang (2010) both developed inverse probability of
censoring weighting methods, while Mart´ınez-Camblor & Pardo-Ferna´ndez (2018) proposed
an approach based on a bivariate kernel density estimator. From a Bayesian perspective,
Zhao et al. (2016) proposed a semiparametric approach that uses a single-weights dependent
Dirichlet process mixture for modelling the conditional distribution of the time to disease
onset given the test outcome. For recent overview articles on this topic see Blanche et al.
(2013) and Kamarudin et al. (2017), where the latter also surveys estimators proposed
under the dynamic and incident definitions. To conclude, we highlight that the inclusion of
covariates, whenever available, in the time-dependent true positive and negative fractions,
should also be done. The covariate-specific time-dependent TPF and TNF, for a covariate
value x, are given by
TPF(c, t | x) = Pr(Y ≥ c | T ≤ t,x), TNF(c, t | x) = Pr(Y < c | T > t,x),
www.annualreviews.org • Statistical Evaluation of Medical Tests 23
with the covariate-specific time-dependent ROC curve and AUC following in a similar fash-
ion. The literature on the estimation of the covariate-specific time-dependent TPF and
TNF is, by comparison, relatively scarce. Important references are Song & Zhou (2008)
and Rodr´ıguez-A´lvarez et al. (2016).
6. SOFTWARE
We start by making the disclaimer that we are not, by no means, doing an exhaus-
tive review and that our focus is the R software. The package pROC (https://CRAN.
R-project.org/package=pROC) provides a set of tools to visualise, smooth, and compare
ROC curves, but covariate information cannot be explicitly taken into account. Pack-
ages ROCRegression and npROCRegression offer functions to estimate semiparametrically
and nonparametrically, under a frequentist framework and using both induced and direct
methodologies, the covariate-specific ROC curve. In particular, ROCRegression (https:
//bitbucket.org/mxrodriguez/rocregression) implements the approaches of Faraggi
(2003), Pepe (1998), Alonzo & Pepe (2002), and Cai (2004), while npROCRegression
(https://CRAN.R-project.org/package=npROCRegression) implements the approaches of
Rodr´ıguez-A´lvarez et al. (2011b) and Rodr´ıguez-A´lvarez et al. (2011a). To the best of our
knowledge, ROCnReg (https://CRAN.R-project.org/package=ROCnReg) is the only R pack-
age that allows conducting Bayesian inference for the ROC curve and related indices (includ-
ing optimal thresholds) estimation. In particular, ROCnReg implements all four nonparamet-
ric approaches for ROC curve estimation described in Section 3.3 and all induced approaches
reviewed in Section 4.3 for the estimation of the covariate-specific ROC curve. ROCnReg also
offers routines for conducting inference about the covariate-adjusted ROC curve. All data
analysis conducted in this article were obtained using ROCnReg (for more details about
the package see Rodriguez-Alvarez & Ina´cio 2020). Also, the package OptimalCutpoints
(https://CRAN.R-project.org/package=OptimalCutpoints) provides a collection of rou-
tines for point and interval estimation of optimal thresholds. Regarding estimation of the
time-dependent ROC curve, the packages survivalROC (https://CRAN.R-project.org/
package=survivalROC), timeROC (https://CRAN.R-project.org/package=timeROC), and
CondTimeROC (https://bitbucket.org/mxrodriguez/condtimeroc) implement some of the
approaches mentioned in Section 5.
7. DISCUSSION AND FURTHER TOPICS
In this article we have reviewed from a high-level perspective some of the main aspects
related to the statistical evaluation of medical tests. We have deliberately chosen to place
special focus on the estimation of ROC curves, with and without covariates, with the case
of time-dependent ROC curves being also covered. As a so broad area, many interesting
topics have had necessarily to be left untouched and we briefly mention some of them below.
The available methodology for the study of the predictive values of continuous tests
is far less extensive than the corresponding methodology for ROC curves. We mention
the predictive receiver operating characteristic (pROC) curve proposed by Shiu & Gat-
sonis (2008) for the joint assessment of the positive and negative predictive values. In
an analogous way to the definition of the ROC curve, the authors defined the pROC as
{1 − NPV(c),PPV(c) : c ∈ R}. One possibility for its estimation is to make use of Equa-
tions 1 and 2 (with the due adaptation that now in the continuous case all quantities are
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a function of the threshold) and then plug these estimates in the definition of the pROC
curve, that is, in order to estimate the pROC curve we only need to estimate the corre-
sponding TPF and FPFs and the prevalence of the disease. A covariate-specific ROC curve
can be defined and estimated in a similar fashion.
Although we have assumed that disease status is binary (disease versus nondisease),
in clinical practice, physicians often face situations that require decisions among three (or
even more) diagnostic alternatives. This is especially true for neurological disorders, where
cognitive function usually declines from normal function to mild impairment, to severe im-
pairment or dementia. ROC surfaces (and the volume under the surface and the generalised
Youden index) have been proposed in the literature as an extension to the three-class case
of ROC curve methodology (Nakas & Yiannoutsos 2004, Nakas et al. 2010). Parametric,
semiparametric and nonparametric estimators do exist and we refer to Nakas (2014) for
a recent overview. ROC surface regression, by opposed to the two-class counterpart, has
received little attention, with Li et al. (2012), to the best of our knowledge, being the only
contribution.
The existence of a gold standard test was assumed throughout this article, but this might
not be the case for some diseases as, for instance, a definitive diagnosis of the Alzheimer’s
disease can only be made through autopsy after death. Approaches for estimating the ROC
curve and the covariate-specific ROC curve in the absence of a gold standard test have been
proposed, among others, by Branscum et al. (2008) and Branscum et al. (2015).
Lastly, in our motivating example, the HOMA-IR levels, our diagnostic test/marker,
was known and given. However, sometimes researchers do have access to multiple tests or
biomarkers on individuals and interest in such cases might lie on how to best combine and
transform this information onto a univariate score, to further use it to diagnose individuals.
The topic of optimal combination of biomarkers using ROC analysis has received consider-
able attention in the literature (see, among many others, Su & Liu 1993, Pepe et al. 2006,
Liu et al. 2011). Recently, methods that deal with optimal biomarker combination but with
covariate adjustment have also been proposed (e.g. Liu & Zhou 2013, Kim & Huang 2017).
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SUPPLEMENTARY MATERIALS
Here we provide supplementary figures and tables to the main document.
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Figure 1
Histograms of the log HOMA IR levels along with the estimated densities produced by a Dirichlet process mixture of
normals model (solid pink line, with the dashed pink lines representing the pointwise 95% credible band) and by a kernel
method (normal kernel and bandwidth selected by Silverman’s rule of thumb) (solid blue line).
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Figure 2
Estimated ROC curve. Here BB stands for the Bayesian bootstrap method (Gu et al. 2008) and DPM for the Dirichlet
process mixture of normals model (Erkanli et al. 2006).
Women Men
Youden index log HOMA-IR optimal threshold Youden index log HOMA-IR optimal threshold
Empirical 0.325 0.742 0.292 0.718
Kernel 0.283 0.804 0.265 0.728
DPM 0.277 (0.197, 0.356) 0.779 (0.660, 0.894) 0.282 (0.210, 0.353) 0.666 (0.557, 0.779)
BB 0.338 (0.249, 0.427) 0.781 (0.695, 0.913) 0.315 (0.237, 0.390) 0.757 (0.400, 0.962)
Table 1 Estimated Youden index and associated log Homa-IR optimal threshold. For
the Bayesian approaches, the numbers in brackets are the 95% credible intervals. Here
BB stands for the Bayesian bootstrap method (Gu et al. 2008) and DPM for the
Dirichlet process mixture of normals model (Erkanli et al. 2006).
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Figure 3
Estimated age/gender-specific Youden index and associated log HOMA-IR optimal thresholds. The continuous lines
correspond to point estimates and the shaded region correspond to the 95% pointwise credible band. Here BNP stands for
the Bayesian nonparametric method of Ina´cio de Carvalho et al. (2013) and Kernel for the approach of Rodr´ıguez-A´lvarez
et al. (2011).
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